News & Updates on our SARS-CoV-2 Research
Since spring 2020, scientists of the Vienna BioCenter have continuously made important contributions to the struggle to control the pandemic. Key developments include self-sampling protocols via gargling, monitoring pipelines, innovative testing methods such as RT-LAMP, mutant strain monitoring via SARSeq, or the development of vaccines and COVID-19 therapeutics.
Below, you find an overview on relevant news items from this challenging but yielding period. This overview list will be continued.
3 June 2021. Valneva announced that it has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
25 May 2021. Researchers at the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is published in the journal Nature Communications and could be adapted to many more pathogens.
19 May 2021. Valneva announced it will participate in a UK government-funded clinical trial looking at different COVID-19 ‘booster’ vaccines.
04 May 2021. CEBINA announced that azelastine is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus.
21 April 2021. Valneva announced it has initiated a pivotal Phase 3 clinical trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
28 JANUARY 2021. Valneva announced it has commenced production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies, in order to optimize the timeline for potential deliveries of the vaccine.
07 DECEMBER 2020. In a pilot project, researchers of the "Vienna Covid-19 Detection Initiative" (VCDI) at the Vienna BioCenter, Caritas of the Archdiocese of Vienna and the association Novid20 show how institutions can continuously screen larger groups of people.
21 OCTOBER 2020. Scientists from the Vienna BioCenter developed a new SARS-CoV-2 detection method: by rather simple means, their RT-LAMP test is cheaper than PCR testing and achieves results with comparable sensitivity and specificity.
24 JUNE 2020. Scientists from the Vienna BioCenter have pushed SARS-CoV-2 detection to a new level. Their approach is as sensitive and robust, yet cheaper, simpler and faster to implement than conventional tests.
04 JUNE 2020. CEBINA announced that it has received seed funding for its extended spectrum Coronavirus vaccine project, which is part of CEBINA’s broad-scale efforts offering short-, mid- and longer-term solutions to fight the COVID-19 pandemic.
17 APRIL 2020. The Austrian biotech incubator and accelerator CEBINA GmbH announces the initiation of several collaborative projects that address the global health crisis caused by the pandemic spread of the SARS-CoV-2 virus.
03 APRIL 2020. The Vienna COVID-19 Diagnostics Initiative (VCDI) is a collaborative effort involving 20 scientific institutions across Vienna. The initiative has repurposed existing infrastructure, resources, and manpower to build a new diagnostics pipeline....
03 APRIL 2020. A team of international scientists with participation of IMBA produced groundbreaking results in blocking viral infections in human organoids by inhibiting interactions with the SARS-CoV-2 receptor ACE2.